Author Interviews, Dermatology, Immunotherapy, Rheumatology / 28.11.2016
No Increased Risk of IBD Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis in Phase 2 & 3 Clinical Studies
MedicalResearch.com Interview with:
Atul Deodhar, M.D., M.R.C.P.
Rheumatology
Oregon Health and Science University
MedicalResearch.com: What is the background for this study?
Response: Patients with psoriasis, psoriatic arthritis (PsA), or ankylosing spondylitis (AS) are at an increased risk of developing inflammatory bowel disease (IBD) compared with the general population. It is important that we assess whether new therapies, including the recently approved interleukin-17A (IL-17A) inhibitor, secukinumab, have an acceptable profile in terms of the risk of IBD in patients with psoriasis, PsA, or AS.
(more…)